|
|
Volumn 17, Issue 12, 2001, Pages 12-15
|
|
Clinical and pharmacoeconomic aspects both play an important role in the treatment of ovarian cancer
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALTRETAMINE;
AMIFOSTINE;
ANTINEOPLASTIC AGENT;
CARBOPLATIN;
CISPLATIN;
CYCLOPHOSPHAMIDE;
DOCETAXEL;
DOXORUBICIN;
ETOPOSIDE;
FLUOROURACIL;
FOLINIC ACID;
GEMCITABINE;
GRANISETRON;
IFOSFAMIDE;
IRINOTECAN;
MELPHALAN;
MESNA;
METOCLOPRAMIDE;
NAVELBINE;
ONDANSETRON;
PACLITAXEL;
TAMOXIFEN;
THIOTEPA;
TOPOTECAN;
ARTICLE;
AUTOLOGOUS BONE MARROW TRANSPLANTATION;
CANCER SURVIVAL;
CONTROLLED STUDY;
COST EFFECTIVENESS ANALYSIS;
DRUG COST;
FEMALE;
HEALTH CARE COST;
HEMATOPOIETIC STEM CELL TRANSPLANTATION;
HUMAN;
HYSTERECTOMY;
MEDICAL DECISION MAKING;
MUCOSA INFLAMMATION;
NAUSEA AND VOMITING;
NEPHROTOXICITY;
NEUTROPENIA;
OVARY CANCER;
PERIPHERAL NEUROPATHY;
QUALITY OF LIFE;
SALPINGOOOPHORECTOMY;
THROMBOCYTOPENIA;
XEROSTOMIA;
|
|
EID: 0035907991
PISSN: 11720360
EISSN: None
Source Type: Journal
DOI: 10.2165/00042310-200117120-00004 Document Type: Article |
|
Times cited : (2)
|
|
References (13)
|
